Safety Policies & Visitor Guidelines |
Appointments & Scheduling |
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Perelman Center for Advanced Medicine
West Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
Penn Medicine Radnor
Floor 2, Suite 200 North
145 King of Prussia Road
Radnor, PA 19087
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
neuroendocrine tumors and esophagogastric cancer
Eads JR, Krishnamurthi SS, Saltzman J, Bokar JA, Savvides P, Meropol NJ, Gibbons J, Koon H, Sharma N, Pink JJ, Xu Y, Beumer JH, Kane D, Rodal MB, Riendeau J, Fu P, Gerson SL, Dowlati A: Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors Investigational New Drugs : 2020.
Heckert JM, Kipnis S, Kumar S, Botterbusch S, Alderson A, Bennett B, Creamer C, Eads JR, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Katona BW: Abnormal pre-treatment liver function tests are associated with discontinuation of PRRT in a U.S.-based neuroendocrine tumor cohort The Oncologist 25 : 1-7,2020.
Eads JR, Weitz M, Gibson MK, Rajdev L, Khullar OV, Lin SH, Gatsonis C, Wistuba II, Sanjeevaiah A, Benson AB, Bahary N, Spencer KR, Saba NF, Hamilton SR, Staley CA, Chakravarthy AB, Wong TZ, O'Dwyer PJ: A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal and gastroesophageal junction adenocarcinoma: a trial of the ECOG-ACRIN cancer research group (EA2174) Journal of Clinical Oncology : 2020.
Lau-Min KS, Li Y, Eads JR, Mamtani R, Getz KD: Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice Journal of Clinical Oncology : 2020.
Dreyfuss AD, Barsky AR, Plastaras JP, Ben-Josef, Eads JR, Metz JM, Wojcieszynski AP: The efficacy of definitive concurrent proton chemoradiotherapy for esophageal cancer PTCOG-NA abstract book : 2019.
Heckert J, Botterbusch S, Kipnis S, Bennet B, Creamer C, Alderson A, Eads J, Soulen M, Pryma D, Mankoff D, Metz D, Katona B: Initial experience with peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumors (NETs) at a tertiary care United States center North American Neuroendocrine Tumor Society Abstract book : 2019.
Barsky AR, Dreyfuss AD, Plastaras JP, Ben-Josef E, Eads JR, Metz JM, Wojcieszynski AP: The toxicity profile of definitive concurrent proton chemoradiothearpy for esophageal cancer PTCOG-NA abstract book : 2019.
Heckert JM, Eads JR, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Katona BW: Initial experience with peptide receptor radionuclide therapy (PRRT) for the treatment of neuroendocrine tumor (NET) at a tertiary care United States center Digestive Disease Week abstract book : 2019.
Lee H, Eads JE, Pryma DA: Standardized uptake values on 68Ga-DOTATATE PET/CT predict response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors Radiological Society of North America (RSNA) 2019 Annual Meeting : 2019.
Eads JR, Krishnamurthi SK, Saltzman JN, Bajor DL, Vinayak S, Barnholtz-Sloan J, Meropol NJ, Markowitz SD, Wang Z: Phase I clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors J Clin Oncol 36 : 2018.
Perelman Center for Advanced Medicine 10th Floor South Pavilion
Patient appointments: 800-789-7366